Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT02449733Completed
Open-label trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Emory University. Primary endpoints: Retention in the cohort at 12 months, Use of PrEP at 6 months and 1 more. Started May 2015; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT02449733.